A Suite of Venous Access Devices

Our technology can be used in a range of clinical settings.

Initially focused on launching our PICC device, the HydroPICC™, we are also in the early stages of development of hemodialysis and implantable port devices.

Access Vascular HydroPICC Illustration



For our first product, the HydroPICC™, we changed the core material from which conventional PICCs are made, switching from polyurethanes to our proprietary bulk hydrophilic material.

The HydroPICC is designed to greatly reduce the need for further modification with additives or coatings to achieve its anti-thrombogenic properties. Our technology is less likely to be recognized by the body as a foreign material and therefore reduces the chance that it will trigger the body’s thrombotic response, the initial trigger to a cascade of events that leads to catheter occlusion and bacterial colonization. The net result will be improved procedural efficiencies, a higher quality of care and improved reimbursement.

Efficacy: Access Vascular has completed benchtop biocompatibility and preclinical studies (where the catheter is indwelling in various animal models), and the material has proven to reduce thrombogenicity. Our testing has demonstrated the potential for superior clinical outcomes and lower healthcare costs compared with existing technologies.

Regulatory Path: We anticipate a successful 510(k) submission and path to commercialization.

Thrombogenicity Testing

Tested for 120 minutes

Competitor A

Competitor B


We will submit a 510(k) application for the HydroPICC in late 2017, and anticipate commercialization launch in early 2018.

Current issues with PICC lines the HydroPICC addresses


of traditional PICCS become occluded


greater DVT risk in upper extremities


of DVTs result in pulmonary embolism


days hospital stays are extended


Patency check required every 8 hours


Central-line Associated Blood Stream Infection